Veröffentlichungen 2004
Publikationen
1. Dietz A, Rudat V, Harms W, Jungehülsing M, Dollner R, Henze M. Diagnosis with (18)F-FDG PET scan after larynx preservation by primary radiochemotherapy. HNO 2004;52:38-44.
2. Dimitrakopoulou-Strauss A, Strauss LG, Burger C, Ruehl A, Irngartinger G, Stremmel W, Rudi J. Prognostic Aspects of 18F-FDG PET Kinetics in Patients with Metastatic Colorectal Carcinoma Receiving Folfox Chemotherapy. J Nucl Med 2004;45:1480-1487.
3. Doll J, Henze M, Bublitz O, Werling A, Adam LE, Haberkorn U, Semmler W, Brix G. High resolution reconstruction of PET images using the iterative OSEM algorithm. Nuklearmedizin 2004;43:72-78.
4. Efferth T, Koomägi R, Mattern J, Volm M. Lung cancer protein expression profiles of smokers and non-smokers. Cancer Genomics Proteomics 2004;1:249-254.
5. Froidevaux S, Calame-Christe M, Schuhmacher J, Tanner H, Saffrich R. Henze M, Eberle AN. A Gallium-labeled DOTA-a-Melanocyte stimulating hormone analog for PET imaging of melanoma metastases. J Nucl Med 2004;45:116-123.
6. Haberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 2004;45:73-76.
7. Haberkorn U, Altmann A, Mier W, Eisenhut M. Impact of functional genomics and proteomics on radionuclide imaging. Sem Nucl Med 2004;34:4-22.
8. Haberkorn U, Beuter P, Kübler W, Eskerski H, Eisenhut M, Kinscherf R, Zitzmann S, Strauss LG, Dimitrakopoulou-Strauss A, Altmann A. Iodide kinetics and dosimetry in vivo after transfer of the human sodium iodide symporter gene in rat thyroid carcinoma cells. J Nucl Med 2004;45:827-833.
9. Henze M, Mohammed A, Schlemmer HP, Herfarth KK, Hoffner S, Haufe S, Mier W, Eisenhut M, Debus J, Haberkorn U. PET and SPECT for detection of tumor progression in irradiated low grade astrocytoma: a receiver-operating-characteristic analysis. J Nucl Med 2004;45:579-586.
10. Henze M, Schuhmacher J, Dimitrakopoulou-Strauss A, Strauss LG, Mäcke HR, Eisenhut M, Haberkorn U. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET. Eur J Nucl Med Mol Imaging 2004;31:466.
11. Kim MK, Zitzmann S, Westermann F, Arnold K, Brouwers S, Schwab M, Savelyeva L. Increased rates of spontaneous sister chromatid exchange in lymphocytes of BRCA2+/- carriers of familial breast cancer clusters. Cancer Lett 2004;210(1):85-94.
12. Korosoglou G, Hansen A, Hoffend J, Gavrilovic G, Wolf D, Zehelein J, Haberkorn U, Kuecherer H. Comparison of real-time myocardial contrast echocardiography for the assessment of myocardial viability with fluorodeoxyglucose-18 positron emission tomography and dobutamine stress echocardiography. Am J Cardiol 2004;94(5):570-576.
13. Lichy MP, Henze M, Plathow C, Bachert P, Kauczor HU, Schlemmer HP. Metabolische Bildgebung zur Verlaufskontrolle stereotaktisch bestrahlter Gliome – Wertigkeit der 1H-MR-Spektroskopie im Vergleich zur FDG-PET und IMT-SPECT. (Metabolic imaging to follow stereotactic radiation of gliomas - the role of 1H MR spectroscopy in comparison to FDG-PET and IMT-SPECT). Rofo 2004;176(8):1114-21.
14. Lichy MP, Bachert P, Henze M, Lichy CM, Debus J, Schlemmer HP. Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy. Neuroradiology 2004;46(2):126-9.
15. Mattern J, Volm M. Imbalance of cell proliferation and apoptosis during progression of lung carcinomas. Anticancer Research 2004;24:4243-4246.
16. Mattern J. Cellular drug resistance in lung cancer. Cancer Ther 2004;2:403-414.
17. Mier W, Gabel D, Haberkorn U, Eisenhut M. Conjugation of the closo-borane mercaptoundeca-hydrododecaborate (BSH) to a tumour selective peptide. Z anorgan allgem Chemie 2004;630:1258-1262.
18. Mier W, Graham KAN, Wang Q, Krämer S, Hoffend J, Eisenhut M, Haberkorn U. Synthesis of peptide conjugated chelator oligomers for endoradiotherapy and MRT imaging. Tetrahedron Letters 2004;45:5433-5455.
19. Munter MW, Karger CP, Hoffner SG, Hof H, Thilmann C, Rudat V, Nill S, Wannenmacher M, Debus J. Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. Int J Radiat Oncol Biol Phys 2004;58(1):175-84.
20. Okouoyo S, Herzer K, Ucur E, Mattern J, Krammer PH, Debatin KM, Herr I: Rescue of death receptor and mitochondrial apoptosis signaling in resistant human NSCLC in vivo. Int J Cancer 2004;108:580-587.
21. Schoensiegel F, Paschen A, Sieger S, Eskerski H, Mier W, Rothfels H, Kleinschmidt J, Schadendorf D, Haberkorn U. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Therapy 2004;11:408-418.
22. Sieger S, Jiang S, Kleinschmidt J, Eskerski H, Schönsiegel F, Altmann A, Mier W, Haberkorn U. Tumor-specific gene expression using regulatory elements of the glucose transporter isoform 1 gene. Cancer Gene Ther 2004;11:41-51.
23. Strauss LG, Dimitrakopoulou-Strauss A, Koczan D, Bernd L, Haberkorn U, Ewerbeck V, Thiesen HJ. 18F-FDG Kinetics and Gene Expression in Giant Cell Tumors. J Nucl Med 2004;45:1528-1535.
24. Thireou T, Kontaxakis G, Strauss LG, Dimitrakopoulou-Strauss A, Pavlopoulos S, Santos A. Feasibility study of the use of similarity maps in the evaluation of oncological dynamic positron emission tomography images. Med Biol Eng Comput 2004;42:1-10.
25. Wang Q, Graham K, Schauer T, Fietz T, Mohammed A, Liu X, Hoffend J, Haberkorn U, Eisenhut M, Mier W. Pharmacological properties of hydrophilic and lipophilic derivatives of octreotate. Nucl Med Biol 2004;31:21-30.
26. Wolf M, Bauder-Wüst U, Mohammed A, Schönsiegel F, Mier W, Haberkorn U, Eisenhut M. Alkylating benzamides with melanoma cytotoxicity. Melanoma Res 2004;14:353-360.
Buchbeiträge
1. Dimitrakopoulou-Strauss A. Positron Emission Tomography (PET) for diagnosis and therapy monitoring in oncology. In: Georgoulias W (ed.) Proceedings of the 11th Meeting for Clinical Oncology. Progresses in Oncology in 2003, Herakleion 2004, pp 13-29.
2. Doll J, Bendl R, Henze M, Höss A, Haberkorn U, Schlegel W. Integration of biological information in precision radiotherapy planning of meningiomas. Proceedings of the XIVth International Conference on the Use of Computers in Radiation Therapy (ICCR) Jeong Publishing, Seoul, Korea B.Y. Yi u.a. (Hrsg), 2004, pp 608-611.
3. Ebert M, Henze M, Hipp P, Schad L. Chapter 3: Imaging – Nuclear Medicine. In: 3D Conformal Radiation Therapy - Multimedia Introduction to Methods and Techniques (Editors: Schlegel W, Mahr A), Springer Verlag, Berlin, Heidelberg, New York 2001; 2nd Edition 2004. ISBN 3540230149.
4. Haberkorn U. Future directions in molecular imaging. In: From morphological Imaging to Molecular Targeting. Ernst Schering Research Foundation Workshop 48. Springer Verlag, Berlin, Heidelberg, New York 2004; pp 111-134. ISBN 3540201378.
5. Haberkorn U. Future clinical applications of PET (amino acid and nucleoside imaging). In: Ell P, Gambhir S (ed.) Nuclear Medicine in Clinical Diagnosis and Treatment, 3rd Ed. 2004, pp 329-344. ISBN 0443073120.
6. Haberkorn U. Nuklearmedizinische Möglichkeiten in der Primärdiagnostik und Follow up des Pleuramesothelioms. In: Das Pleuramesotheliom (Hrsg. Manegold): 2004, S. 15-21. ISBN 3540230149.
7. Hünerbein R, Jäkel O, Karger C, Schulz-Ertner D, Henze M, Haberkorn U. Nuklearmedizin. In: Reiser M, Kuhn F-P, Debus J (ed.) Radiologie, Thieme-Verlag Stuttgart, 2004, pp 140-147. ISBN 3131253215.